Skip to main content
SpringerLink
Log in
Book cover

Regional Chemotherapy pp 339–356Cite as

Regional Chemotherapy for Treatment and Prophylaxis of Meningeal Leukemia

  • Chapter

  • 100 Accesses

Part of the book series: Current Clinical Oncology ((CCO))

Abstract

Clinicians recognized the importance of the central nervous system (CNS) as a sanctuary for leukemia cells only when improved treatments began to lengthen the survival of children with acute lymphoblastic leukemia (ALL) Subsequent efforts to treat and prevent meningeal leukemia are partially responsible for the dramatic success in curing childhood ALL. Meningeal leukemia also complicates adult acute leukemia, but higher cure rates have been more elusive in adults. The efforts of early investigators have rendered overt meningeal leukemia uncommon, and recent studies of prophylactic regimens have sought to reduce toxicity, rather than to improve efficacy. However, despite effective prophylaxis, overt meningeal leukemia still occurs, and regional chemotherapy plays an important role in its management.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Price RA and Johnson WW. Central nervous system in childhood leukemia: I. The arachnoid, Cancer, 31 (1973) 520–533.

    Article  PubMed  CAS  Google Scholar 

  2. Bleyer WA. Biology and pathogenesis of CNS leukemia, Am. J. Pediatr. Hematol. Oncol., 11 (1989) 57–63.

    Article  PubMed  CAS  Google Scholar 

  3. Hardisty RM and Norman PM. Meningeal leukaemia, Arch. Dis. Child., 42 (1967) 441–447.

    Article  PubMed  CAS  Google Scholar 

  4. Law IP and Blom J. Adult acute leukemia: frequency of central system involvement in long-term survivors, Cancer, 40 (1977) 1304–1306.

    Article  PubMed  CAS  Google Scholar 

  5. Stewart DJ, Keating MJ, McCredie KB, et al. Natural history of central nervous system acute leukemia in adults, Cancer, 47 (1981) 184–196.

    Article  PubMed  CAS  Google Scholar 

  6. Bigner SH. Cerebrospinal fluid (CSF) cytology: current status and diagnostic applications, J. Neuropathol. Exp. Neurol., 51 (1992) 235–45.

    Article  PubMed  CAS  Google Scholar 

  7. Hyman CB, Bogle JM, Brubaker CA, Williams K, and Hammond D. Central nervous system involvement by leukemia in children. I. Relationship to systemic leukemia and description of clinical and laboratory manifestations, Blood, 25 (1965) 1–12.

    PubMed  CAS  Google Scholar 

  8. Lauer SJ, Kirchner PA, and Camitta BM. Identification of leukemic cells in the cerebrospinal fluid from children with acute lymphoblastic leukemia: advances and dilemmas, Am. J. Pediatr. Hematol. Oncol., 11 (1989) 64–73.

    Article  PubMed  CAS  Google Scholar 

  9. Mastrangelo R, Poplack D, Bleyer A, Riccardi R, Sather H, and D’Angio G. Report and recommendations of the Rome workshop concerning poor-prognosis acute lymphoblastic leukemia in children: biologic bases for staging, stratification, and treatment, Med. Pediatr. Oncol., 14 (1986) 191–194.

    Article  PubMed  CAS  Google Scholar 

  10. Mahmoud HH, Rivera GK, Hancock ML, et al. Low leukocyte counts with blast cells in cerebrospinal fluid of children with newly diagnosed acute lymphoblastic leukemia, N. Engl. J. Med., 329 (5) (1993) 314–319.

    Article  PubMed  CAS  Google Scholar 

  11. Donskoy E, Tausche F, Altman A, Quinn J, and Goldschneider I. Association of immunophenotype with cerebrospinal fluid involvement in childhood B-lineage acute lymphoblastic leukemia, Am. J. Clin. Pathol., 107 (1997) 608–616.

    PubMed  CAS  Google Scholar 

  12. Oberg G, Hallgren R, Fenge P. 132-Microglobulin, lysozyme, and lactoferrin in cerebrospinal fluid in patients with lymphoma or leukaemia: relationship to CNS involvement and the effect of prophylactic intrathecal treatment with methotrexate, Br. J. Haematol., 66 (1987) 315–322.

    Article  PubMed  CAS  Google Scholar 

  13. Hansen PB, Kjeldsen L, Dalhoff K, and Olesen B. Cerebrospinal fluid beta-2-microglobulin in adult patients with acute leukemia or lymphoma: a useful marker in early diagnosis and monitoring of CNS involvement, Acta. Neurol. Scand., 85 (1992) 224–227.

    Article  PubMed  CAS  Google Scholar 

  14. Kersten MJ, Evers LM, Dellemijn PLI, et al. Elevation of cerebrospinal fluid soluble CD27 levels in patients with meningeal localization of lymphoid malignancies, Blood, 87 (1996) 1985–1989.

    PubMed  CAS  Google Scholar 

  15. Evans AE, Gilbert ES, and Zandstra R. Increasing incidence of central nervous system leukemia in children, Cancer, 26 (1970) 404–409.

    Article  PubMed  CAS  Google Scholar 

  16. Aur RJA, Simone J, Hustu O, et al. Central nervous system therapy and combination chemotherapy of childhood lymphocytic leukemia, Blood, 37 (1971) 272–281.

    PubMed  CAS  Google Scholar 

  17. Gottlieb AJ, Weinberg V, Ellison RR, et al. Efficacy of daunorubicin in the therapy of adult acute lymphocyte leukemia: a prospective randomized trial by the Cancer and Leukemia Group B, Blood, 64 (1984) 267–274.

    PubMed  CAS  Google Scholar 

  18. Cortes J, O’Brien SM, Pierce S, et al. Value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia, Blood, 86 (1995) 2091–2097.

    PubMed  CAS  Google Scholar 

  19. Omura GA, Moffitt S, Vogler WR, and Salter MM. Combination chemotherapy of adult acute lymphoblastic leukemia with randomized central nervous system prophylaxis, Blood, 55 (1980) 199–204.

    PubMed  CAS  Google Scholar 

  20. Dekker AW, Elderson A, Punt K, and Sixma JJ. Meningeal involvement in patients with acute nonlymphocytic leukemia. Incidence, management, and predictive factors, Cancer, 56 (1985) 2078–2082.

    Article  PubMed  CAS  Google Scholar 

  21. Brinch L, Evensen SA, Stavem P. Leukemia in the central nervous system, Acta. Med. Scand., 224 (1988) 173–178.

    Article  PubMed  CAS  Google Scholar 

  22. Holmes R, Keating M, Cork A, et al. Unique pattern of central nervous system leukemia in acute myelomonocytic leukemia associated with inv(16)(p13g22), Blood, 65 (1985) 1071–1078.

    PubMed  CAS  Google Scholar 

  23. Tobelem G, Jacquillat C, Chastang C, et al. Acute monoblastic leukemia: a clinical and biologic study of 74 cases, Blood, 55 (1980) 71–76.

    PubMed  CAS  Google Scholar 

  24. Armitago JO and Burns CP. Maintenance therapy of adult acute nonlymphoblastic leukemia: an argument against the need for central nervous system prophylaxis, Cancer, 41 (1978) 697–700.

    Article  Google Scholar 

  25. Mandelli F, De Lipsis E, Grignani F, et al. Daunomycin, cytosine arabinoside and 6-thioguanine (DAT) vs vincristine, cytosine arabinoside and 6-thioguanine (VAT) in the induction treatment of acute nonlymphocyte leukemia: a randomized collaborative study, Med. Pediatr. Oncol., 4 (1978) 231–240.

    Article  PubMed  CAS  Google Scholar 

  26. Janvier M, Tobelem G, Daniel MT, Bernheim A, Marty M, and Boiron M. Acute monoblastic leukaemia. Clinical, biological data and survival in 45 cases, Scand. J. Haematol., 32 (1984) 385–390.

    Article  PubMed  CAS  Google Scholar 

  27. Cash J, Fehir KM, and Pollack MS. Meningeal involvement in early stage chronic lymphocytic leukemia, Cancer, 59 (1987) 798–800.

    Article  PubMed  CAS  Google Scholar 

  28. Davies GE. Meningeal leukemia complicating chronic lymphocytic leukemia, Cancer 50 (1982) 605–606.

    Article  PubMed  CAS  Google Scholar 

  29. Liepman MK and Votaw ML. Meningeal leukemia complicating chronic lymphocytic leukemia, Cancer, 47 (1981) 2482–2484.

    Article  PubMed  CAS  Google Scholar 

  30. Navarrete D and Bodega E. Leukemic meningitis in a patient with hairy cell leukemia. A case report, Nouv. Rev. Fr. Hematol., 29 (1987) 247–249.

    PubMed  CAS  Google Scholar 

  31. Melhorn DK, Gross S, Fisher BJ, and Newman AJ. Studies on the use of “prophylactic” intrathecal amethopterin in childhood leukemia, Blood, 35 (1970) 55–60.

    Google Scholar 

  32. West RJ, Graham-Pole J, Hardisty RM, and Pike MC. Factors in the pathogenesis of central nervous system leukemia, Br. Med. J., 3 (1972) 311–314.

    Article  PubMed  CAS  Google Scholar 

  33. Gill PS, Meyer PR, Pavlova Z, and Levine AM. B-cell acute lymphocytic leukemia in adults. Clinical, morphological, and immunologic findings, J. Clin. Oncol., 4 (1986) 737–743.

    PubMed  CAS  Google Scholar 

  34. Coleman CN, Cohen JR, Burke JS, and Rosenberg SA. Lymphoblastic lymphoma in adults: results of a pilot protocol, Blood, 57 (1981) 679–84.

    PubMed  CAS  Google Scholar 

  35. Sweetenham JW, Mead GM, and Whitehouse JM. Adult lymphoblastic lymphoma: high incidence of central nervous system relapse in patients treated with the Stanford University protocol, Ann. Oncol., 3 (1992) 839–841.

    PubMed  CAS  Google Scholar 

  36. Kantarjian HM, Walters RS, Smith TL, et al. Identification of risk groups for development of central nervous system leukemia in adults with acute lymphocytic leukemia, Blood, 72 (1988) 1784–1789.

    PubMed  CAS  Google Scholar 

  37. Hyman CB, Bogle JM, Brubaker CA, Williams K, and Hammond D. Central nervous system involvement by leukemia in children. II. Therapy with intrathecal methotrexate, Blood, 25 (1965) 13–22.

    PubMed  CAS  Google Scholar 

  38. George SL, Ochs JJ, Mauer AM, and Simone JV. Importance of an isolated central nervous system relapse in children with acute lymphoblastic leukemia, J. Clin. Oncol., 3 (1985) 776–781.

    PubMed  CAS  Google Scholar 

  39. Gribbin MA, Hardisty RM, and Chessels JM. Long-term control of central nervous system leukemia, Arch. Dis. Child., 52 (1977) 673–678.

    Article  PubMed  CAS  Google Scholar 

  40. Stewart DJ, Smith TL, Keating MJ, et al. Remission from central nervous system involvement in adults with acute leukemia. Effect of intensive therapy and prognostic factors, Cancer, 56 (1985) 632–641.

    Article  PubMed  CAS  Google Scholar 

  41. Nesbit ME, D’Angio GJ, Sather HN, et al. Effect of isolated central nervous system leukaemia on bone marrow remission and survival in childhood acute lymphoblastic leukaemia, Lancet, 1 (1981) 1386–1388.

    Article  Google Scholar 

  42. Ortega JA, Nesbit ME, Sather HN, Robison LL, D’Angio GJ, and Hammond GD. Long-term evaluation of a CNS prophylaxis trial-treatment comparisons and outcome after CNS relapse in childhood ALL: a report from the Children’s Cancer Study Group, J. Clin. Oncol., 5 (1987) 1646–1654.

    PubMed  CAS  Google Scholar 

  43. Behrendt H, van Leeuwen EF, Schuwirth C, et al. Significance of an isolated central nervous system relapse, occurring as first relapse in children with acute lymphoblastic leukemia, Cancer, 63 (1989) 2066–2072.

    Article  PubMed  CAS  Google Scholar 

  44. Ochs JJ, Rivera G, Aur RJ, Hustu HO, Berg R, and Simone JV. Central nervous system morbidity following an initial isolated central nervous system relapse and its subsequent therapy in childhood acute lymphoblastic leukemia, J. Clin. Oncol., 3 (1985) 622–626.

    PubMed  CAS  Google Scholar 

  45. Winick NJ, Smith SD, Shuster J, et al. Treatment of CNS relapse in children with acute lymphoblastic leukemia: a Pediatric Oncology Group study, J. Clin. Oncol., 11 (1993) 271–278.

    PubMed  CAS  Google Scholar 

  46. Ribeiro RC, Rivera GK, Hudson M, et al. Intensive re-treatment protocol for children with an isolated CNS relapse of acute lymphoblastic leukemia, J. Clin. Oncol., 13 (1995) 333–338.

    PubMed  CAS  Google Scholar 

  47. Nesbit ME Jr., GJ DA, Sather HN, Robison LL, Ortega JA, and Hammond D. Post-induction treatment of childhood acute lymphocytic leukemia, N. Engl. J. Med., 310 (1984) 262–263.

    Article  PubMed  Google Scholar 

  48. Evans AE, D’Angio GJ, and Mitus A. Central nervous system complications of children with acute leukemia, J. Pediatr., 64 (1964) 94–96.

    Article  PubMed  CAS  Google Scholar 

  49. Humphrey GB, Krous HF, Filler J, Maxwell JD, and Van Houtte JJ. Treatment of overt CNS leukemia, Am. J. Pediatr. Hematol.-Oncol., 1 (1979) 37–47.

    PubMed  CAS  Google Scholar 

  50. Gomez-Almaguer D, Gonzalez-Llano O, Montemayor J, Jaime-Perez JC, and Galindo C. Dexamethasone in the treatment of meningeal leukemia, Am. J. Hematol., 49 (1995) 353–354.

    Article  PubMed  CAS  Google Scholar 

  51. Gray JR and Wallner KE. Reversal of cranial nerve dysfunction with radiation therapy in adults with lymphoma and leukemia, Int. J. Radiat. Oncol. Biol. Phys., 19 (1990) 439–444.

    Article  PubMed  CAS  Google Scholar 

  52. Duttera MJ, Bleyer WA, Pomeroy TC, Leventhal CM, and Leventhal BG. Irradiation, methotrexate toxicity, and the treatment of meningeal leukemia, Lancet, 2 (1973) 703–707.

    Article  PubMed  CAS  Google Scholar 

  53. Sullivan MP, Humphrey GB, Vietti TJ, Haggard ME, and Lee E. Superiority of conventional intrathecal methotrexate therapy with maintenance over intensive intrathecal methotrexate therapy, unmaintained, or radiotherapy (2000–2500 rads tumor dose) in treatment for meningeal leukemia, Cancer, 35 (1975) 1066–1073.

    Article  PubMed  CAS  Google Scholar 

  54. Steinherz P, Jereb B, and Galicich J. Therapy of CNS leukemia with intraventricular chemotherapy and low-dose neuraxis radiotherapy, J. Clin. Oncol., 3 (1985) 1217–26.

    PubMed  CAS  Google Scholar 

  55. Kun LE, Camitta BM, Mulhern RK, et al. Treatment of meningeal relapse in childhood acute lymphoblastic leukemia. I. Results of craniospinal irradiation, J. Clin. Oncol., 2 (1984) 359–364.

    PubMed  CAS  Google Scholar 

  56. Whiteside JA, Philips FS, Dargeon HW, and Burchenal JH. Intrathecal amethopterin in neurological manifestations of leukemia, Arch. Intern. Med., 101 (1958) 279–285.

    Article  CAS  Google Scholar 

  57. Ommaya AK. Implantable devices for chronic access and drug delivery to the central nervous system, Cancer Drug Deliv., 1 (1984) 169–179.

    Article  PubMed  CAS  Google Scholar 

  58. Shapiro WR, Young DF, and Mehta BM. Methotrexate distribution in cerebrospinal fluid after intravenous, ventricular, and intralumbar injections, N. Engl. J. Med., 293 (1975) 161–166.

    Article  PubMed  CAS  Google Scholar 

  59. Balis FM and Poplack DG. Central nervous system pharmacology of antileukemic drugs, Am. J. Pediatr. Hematol.-Oncol., 11 (1989) 74–86.

    Article  PubMed  CAS  Google Scholar 

  60. lacoangeli M, Roselli R, Pagano L, et al. Intrathecal chemotherapy for treatment of overt meningeal leukemia: comparison between intraventricular and traditional intralumbar route, Ann. Oncol., 6 (1995) 377–382.

    Google Scholar 

  61. Green DM, West CR, Brecher ML, et al. Use of subcutaneous cerebrospinal fluid reservoirs for the prevention and treatment of meningeal relapse of acute lymphoblastic leukemia, Am. J. Pediatr. Hematol.-Oncol., 4 (1982) 147–154.

    PubMed  CAS  Google Scholar 

  62. Colamaria V, Caraballo R, Borgna-Pignatti C, et al. Transient focal leukoencephalopathy following intraventricular methotrexate and cytarabine. A complication of the Ommaya reservoir: case report and review of the literature, Childs Nerv. Syst., 6 (1990) 231–235.

    Article  PubMed  CAS  Google Scholar 

  63. Lishner M, Perrin RG, Feld R, et al. Complications associated with Ommaya reservoirs in patients with cancer. The Princess Margaret Hospital experience and a review of the literature, Arch. Intern. Med., 150 (1990) 173–176.

    Article  PubMed  CAS  Google Scholar 

  64. Bleyer WA and Poplack DG. Intraventricular versus intralumbar methotrexate for central nervous system leukemia, Med. Pediatr. Oncol., 6 (1979) 207–213.

    Article  PubMed  CAS  Google Scholar 

  65. Spiers ASD and Booth AE. Reservoirs for intraventricular chemotherapy, Lancet (1973) 1263.

    Google Scholar 

  66. Pinkel D and Woo S. Prevention and treatment of meningeal leukemia in children, Blood, 84 (1994) 355–366.

    PubMed  CAS  Google Scholar 

  67. Echelberger CK, Riccardi R, Bleyer A, Levin AS, and Poplack DG. Influence of body position on ventricular cerebrospinal fluid (CSF) methotrexate (MTX) concentration following intralumbar (IL) administration, Proc. Am. Soc. Clin. Oncol., 22 (1981) 365a.

    Google Scholar 

  68. Willoughby MLN. Treatment of overt meningeal leukemia in children: results of second MRC meningeal leukaemia trial, Br. Med. J., 1 (1976) 864–867.

    Article  PubMed  CAS  Google Scholar 

  69. Ho DHW. Distribution of kinase and deaminase of 1–13D-arabinofuranosyl-cytosine in tissues of man and mouse, Cancer Res., 33 (1973) 2816–2820.

    PubMed  CAS  Google Scholar 

  70. Bekassy AN, Liliemark J, Garwicz S, Wiebe T, Gulliksson H, and Peterson C. Pharmacokinetics of cytosine arabinoside in cerebrospinal fluid and of its metabolite in leukemic cells, Med. Pediatr. Oncol., 18 (1990) 136–142.

    Article  PubMed  CAS  Google Scholar 

  71. Zimm S, Collins JM, Miser J, Chatterji D, and Poplack DG. Cytosine arabinoside cerebrospinal fluid kinetics, Clin. Pharmacol. Ther., 35 (1984) 826–30.

    Article  PubMed  CAS  Google Scholar 

  72. Wang JJ and Pratt CB. Intrathecal arabinosyl cytosine in meningeal leukemia, Cancer, 25 (1970) 531–534.

    Article  PubMed  CAS  Google Scholar 

  73. Band PR, Holland JF, Bernard J, Weil M, Walker M, and Rall D. Treatment of central nervous system leukemia with intrathecal cytosine arabinoside, Cancer, 32 (1973) 744–748.

    Article  PubMed  CAS  Google Scholar 

  74. Komp DM, Fernandez CH, Falleta JM, et al. CNS prophylaxis in acute lymphoblastic leukemia. Comparison of two methods: a Southwest Oncology Group Study, Cancer, 50 (1982) 1031–1036.

    Article  PubMed  CAS  Google Scholar 

  75. Mahoney DH Jr, Camitta BM, Leventhal BG, et al. Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study, Cancer, 75 (1995) 2623–31.

    Article  PubMed  Google Scholar 

  76. Mahoney DH, Shuster J, Nitschke R, et al. Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group Phase III Trial, J. Clin. Oncol., 16 (1998) 246–254.

    PubMed  CAS  Google Scholar 

  77. Buhrer C, Hartmann R, Fengler R, et al. Importance of effective central nervous system therapy in isolated bone marrow relapse of childhood acute lymphoblastic leukemia. BFM (Berlin-FrankfurtMunster) Relapse Study Group, Blood, 83 (1994) 3468–72.

    PubMed  CAS  Google Scholar 

  78. Giannone L, Greco FA, and Hainsworth JD. Combination intraventricular chemotherapy for meningeal neoplasia, J. Clin. Oncol., 4 (1986) 68–73.

    PubMed  CAS  Google Scholar 

  79. Hasle H, Helgestad J, Christensen JK, Jacobsen BB, and Kamper J. Prolonged intrathecal chemotherapy replacing cranial irradiation in high-risk acute lymphatic leukaemia: long-term follow up with cerebral computed tomography scans and endocrinological studies, Eur. J. Pediatr., 154 (1995) 24–29.

    Article  PubMed  CAS  Google Scholar 

  80. Hoelzer D, Ludwig WD, Thiel E, et al. Improved outcome in adult B-cell acute lymphoblastic leukemia, Blood, 87 (1996) 495–508.

    PubMed  CAS  Google Scholar 

  81. Lauer SJ, Camitta BM, Leventhal BG, et al. Intensive alternating drug pairs for treatment of high-risk childhood acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study, Cancer, 71 (1993) 2854–2861.

    Article  PubMed  CAS  Google Scholar 

  82. Pullen J, Boyett J, Shuster J, et al. Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukemia: a Pediatric Oncology Group study, J. Clin. Oncol., 11 (1993) 839–849.

    PubMed  CAS  Google Scholar 

  83. Sullivan MP, Brecher M, Ramirez I, et al. High-dose cyclophosphamide-high-dose methotrexate with coordinated intrathecal therapy for advanced nonlymphoblastic lymphoma of childhood: results of a Pediatric Oncology Group study, Am. J. Pediatr. Hematol.-Oncol., 13 (1991) 288–295.

    Article  PubMed  CAS  Google Scholar 

  84. Gutin PH, Levi JA, Wiernik PH, and Walker MD. Treatment of malignant meningeal disease with intrathecal thioTEPA: a phase II study, Cancer Treat. Rep., 61 (1977) 885–887.

    PubMed  CAS  Google Scholar 

  85. Strong JM, Collins JM, Lester C, and Poplack DG. Pharmacokinetics of intraventricular and intravenous N,N’,N“-triethylenethiophosphoramide (thiotepa) in rhesus monkeys and humans, Cancer Res., 46 (1986) 6101–6104.

    PubMed  CAS  Google Scholar 

  86. Trump DL, Grossman SA, Thompson G, Murray K, and Wharam M. Treatment of neoplastic meningitis with intraventricular thiotepa and methotrexate, Cancer Treat. Rep., 66 (1982) 1549–1551.

    PubMed  CAS  Google Scholar 

  87. Kim S, Khatibi S, Howell SB, McCully C, Balis FM, and Poplack DG. Prolongation of drug exposure in cerebrospinal fluid by encapsulation into DepoFoam, Cancer Res., 53 (1993) 1596–1598.

    PubMed  CAS  Google Scholar 

  88. Kim S, Chatelut E, Kim JC, et al. Extended CSF cytarabine exposure following intrathecal administration of DTC 101, J. Clin. Oncol., 11 (1993) 2186–2193.

    PubMed  CAS  Google Scholar 

  89. Chamberlain MC, Khatibi S, Kim JC, Howell SB, Chatelut E, and Kim S. Treatment of leptomeningeal metastasis with intraventricular administration of depot cytarabine (DTC 101). A phase I study, Arch. Neurol., 50 (1993) 261–264.

    Article  PubMed  CAS  Google Scholar 

  90. Berg SL, Balis FM, Zimm S, et al. Phase I/II trial and pharmacokinetics of intrathecal diaziquone in refractory meningeal malignancies, J. Clin. Oncol., 10 (1992) 143–148.

    PubMed  CAS  Google Scholar 

  91. Adamson PC, Balis FM, Arndt CA, et al. Intrathecal 6-mercaptopurine: preclinical pharmacology, phase 1/II trial, and pharmacokinetic study, Cancer Res., 51 (1991) 6079–6083.

    PubMed  CAS  Google Scholar 

  92. van der Gaast A, Sonneveld P, Mans DRA, and Splinter TA. Intrathecal administration of etoposide in the treatment of malignant meningitis: feasibility and pharmacokinetic data, Cancer Chemother. Pharmacol., 29 (1992) 335–337.

    Article  PubMed  Google Scholar 

  93. Bleyer WA. Clinical pharmacology of intrathecal methotrexate. II. An improved dosage regimen derived from age-related pharmacokinetics, Cancer Treat. Rep., 61 (1977) 1419–1425.

    PubMed  CAS  Google Scholar 

  94. Haghbin M and Galicich JH. Use of the Ommaya reservoir in the prevention and treatment of CNS leukemia, Am. J. Pediatr. Hematol./Oncol., 1 (1979) 111–117.

    CAS  Google Scholar 

  95. Sullivan MP, Vietti TS, Fembach DJ, Griffith KM, Haddy TB, and Watkins WL. Clinical investigations in the treatment of meningeal leukemia: radiation therapy regimens vs conventional intrathecal methotrexate, Blood, 34 (1969) 301–319.

    PubMed  CAS  Google Scholar 

  96. Bleyer WA, Poplack DG, and Simon RM. “Concentration x time” methotrexate via a subcutaneous reservoir: a less toxic regimen for intraventricular chemotherapy of central nervous system neoplasms, Blood, 51 (1978) 835–842.

    PubMed  CAS  Google Scholar 

  97. Sullivan MP, Vietti TS, Haggard ME, Donaldson MH, Krall JM, and Gehan EA. Remission maintenance therapy for meningeal leukemia: intrathecal methotrexate vs intravenous bis-nitrosurea, Blood, 38 (1971) 680–688.

    PubMed  CAS  Google Scholar 

  98. Balis FM, Savitch JL, Bleyer WA, Reaman GH, and Poplack DG. Remission induction of meningeal leukemia with high-dose intravenous methotrexate, J. Clin. Oncol., 3 (1985) 485–489.

    PubMed  CAS  Google Scholar 

  99. Freeman AI, Boyett JM, Glicksman AS, et al. Intermediate-dose methotrexate versus cranial irradiation in childhood acute lymphoblastic leukemia: a ten-year follow-up, Med. Pediatr. Oncol., 28 (1997) 98–107.

    Article  PubMed  CAS  Google Scholar 

  100. Mona E, Lazzarino M, Brusamolino E, et al. Role of systemic high-dose cytarabine in the treatment of central nervous system leukemia. Clinical results in 46 patients, Cancer, 72 (1993) 439–445.

    Article  Google Scholar 

  101. Frick J, Ritch PS, Hansen RM, and Anderson T. Successful treatment of meningeal leukemia using systemic high-dose cytosine arabinoside, J. Clin. Oncol., 2 (1984) 365–368.

    PubMed  CAS  Google Scholar 

  102. Pinkel D, Simone J, Husto O, and Aur RJA. Nine year’s experience with “Total Therapy” of childhood acute lymphocytic leukemia, Pediatrics, 50 (1972) 246–251.

    PubMed  CAS  Google Scholar 

  103. Pinkel D. Ninth annual David Karnofsky Lecture. Treatment of acute lymphocytic leukemia, Cancer, 43 (1979) 1128–1137.

    Article  PubMed  CAS  Google Scholar 

  104. Soni SS, Marten GW, Pitner SE, Duenas DA, and Powazek M. Effects of central nervous system irradiation on neuropsychologic functioning of children with acute lymphocytic leukemia, N. Engl. J. Med., 293 (1975) 113–118.

    Article  PubMed  CAS  Google Scholar 

  105. Price RA and Jamieson PA. Central nervous system in childhood leukemia. II. Subacute leukoencephalopathy, Cancer, 35 (1975) 306–318.

    Article  PubMed  CAS  Google Scholar 

  106. Nesbit ME Jr, Sather HN, Robison LL, et al. Presymptomatic central nervous system therapy in previously untreated childhood acute lymphoblastic leukaemia: comparison of 1800 rad and 2400 rad. A report for Children’ s Cancer Study Group, Lancet, 1 (1981) 461–466.

    Article  PubMed  Google Scholar 

  107. Sullivan MP, Chen T, Dyment PG, Hvizdala E, and Steuber CP. Equivalence of intrathecal chemotherapy and radiotherapy as central nervous system prophylaxis in children with acute lymphatic leukemia: a Pediatric Oncology Group study, Blood, 60 (1982) 948–958.

    PubMed  CAS  Google Scholar 

  108. Littman P, Coccia P, Bleyer WA, et al. Central nervous system (CNS) prophylaxis in children with low risk lymphoblastic leukemia (ALL), Int. J. Radiat. Oncol. Biol. Phys., 13 (1987) 1443–1449.

    Article  PubMed  CAS  Google Scholar 

  109. Conter V, Schrappe M, Arico M, et al. Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Munster groups, J. Clin. Oncol., 15 (1997) 2786–2791.

    PubMed  CAS  Google Scholar 

  110. Krance RA, Newman EM, Ravindranath Y, et al. Pilot study of intermediate-dose methotrexate and cytosine arabinoside, “spread-out” and “up-front,” in continuation therapy for childhood non-T, non-B acute lymphoblastic leukemia. A Pediatric Oncology Group study, Cancer, 67 (1991) 550–556.

    Article  PubMed  CAS  Google Scholar 

  111. Camitta B, Leventhal B, Lauer S, et al. Intermediate-dose intravenous methotrexate and mercaptopuline therapy for non-T, non-B acute lymphocytic leukemia of childhood: a Pediatric Oncology Group study, J. Clin. Oncol., 7 (1989) 1539–1544.

    PubMed  CAS  Google Scholar 

  112. Poplack D, Reaman G, Bleyer A, et al. Central nervous system preventive therapy with high-dose methotrexate in acute lymphoblastic leukemia: a preliminary report, Proc. Am. Soc. Clin. Oncol., 3 (1984) 204a.

    Google Scholar 

  113. Tubergen DG, Gilchrist GS, O’Brien RT, et al. Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: a Childrens Cancer Group report, J. Clin. Oncol., 11 (1993) 520–526.

    PubMed  CAS  Google Scholar 

  114. Poplack DG, Reaman GH, Bleyer WA, et al. Successful prevention of central nervous system leukemia without cranial radiation in children with high-risk acute lymphoblastic leukemia, Proc. Am. Soc. Clin. Oncol., 8 (1989) 213a.

    Google Scholar 

  115. Ellison RR, Mick R, Cuttner J, et al. Effects of postinduction intensification treatment with cytarabine and daunorubicin in adult acute lymphocytic leukemia: a prospective randomized clinical trial by Cancer and Leukemia Group B, J. Clin. Oncol., 9 (1991) 2002–2015.

    PubMed  CAS  Google Scholar 

  116. Lister TA, Whitehouse JMA, Beard MEJ, et al. Combination chemotherapy for acute lymphoblastic leukaemia in adults, Br. Med. J., 1 (1978) 199–203.

    Article  PubMed  CAS  Google Scholar 

  117. Henderson ES, Scharlau C, Cooper MR, et al. Combination chemotherapy and radiotherapy for acute lymphocytic leukemia in adults: results of CALGB protocol 7113, Leukemia Res., 3 (1979) 395–407.

    Article  CAS  Google Scholar 

  118. Ochs JJ. Neurotoxicity due to central nervous system therapy for childhood leukemia, Am. J. Pediat. Hematol. Oncol., 11 (1989) 93–105.

    Article  CAS  Google Scholar 

  119. Pizzo PA, Poplack DG, and Bleyer WA. Neurotoxicities of current leukemia therapy, Am. J. Pediatr. Hematol.-Oncol., 1 (1979) 127–140.

    PubMed  CAS  Google Scholar 

  120. Bleyer WA, Drake JC, and Chabner BA. Neurotoxicity and elevated cerebrospinal-fluid methotrexate concentration in meningeal leukemia, N. Engl. J. Med., 289 (1973) 770–773.

    Article  PubMed  CAS  Google Scholar 

  121. Ettinger U, Chervinsky DS, Freeman AI, and Creaven PJ. Pharmacokinetics of methotrexate following intravenous and intraventricular administration in acute lymphocytic leukemia and non-Hodgkin’s lymphoma, Cancer, 50 (1982) 1676–1682.

    Article  PubMed  CAS  Google Scholar 

  122. Lopez-Andreu JA, Ferris J, Verdeguer A, Esquembre C, and Castel V. Myelopathy after intrathecal chemotherapy: a case report with unique magnetic resonance imaging changes, Cancer, 75 (1995) 1216–1217.

    Article  PubMed  CAS  Google Scholar 

  123. McLean DR, Clink HM, Ernst P, et al. Myelopathy after intrathecal chemotherapy. A case report with unique magnetic resonance imaging changes, Cancer, 73 (1994) 3037–3040.

    Article  PubMed  CAS  Google Scholar 

  124. Watterson J, Toogood I, Nieder M, et al. Excessive spinal cord toxicity from intensive central nervous system-directed therapies, Cancer, 74 (1994) 3034–3041.

    Article  PubMed  CAS  Google Scholar 

  125. Walker RW. Neurologic complications of leukemia, Neurol. Clin., 9 (1991) 989–999.

    PubMed  CAS  Google Scholar 

  126. Werner RA. Paraplegia and quadriplegia after intrathecal chemotherapy, Arch. Phys. Med. Rehab., 69 (1988) 1054–1056.

    CAS  Google Scholar 

  127. Addiego JE Jr, Ridgway D, and Bleyer WA. Acute management of intrathecal methotrexate overdose: pharmacologic rationale and guidelines, J. Pediatr., 98 (1981) 825–828.

    Article  PubMed  Google Scholar 

  128. Jardine LF, Ingram LC, and Bleyer WA. Intrathecal leucovorin after intrathecal methotrexate overdose, J. Pediatr. Hematol.-Oncol., 18 (1996) 302–304.

    Article  PubMed  CAS  Google Scholar 

  129. O’Marcaigh AS, Johnson CM, Smithson WA, et al. Successful treatment of intrathecal methotrexate overdose by using ventriculolumbar perfusion and intrathecal instillation of carboxypeptidase G2, Mayo Clin. Proc., 71 (1996) 161–165.

    Article  PubMed  Google Scholar 

  130. Allen JC. Effects of cancer therapy on the nervous system, J. Pediatr., 93 (1978) 903–909.

    Article  PubMed  CAS  Google Scholar 

  131. Casteels-van Daele M and van de Casseye W. Acute encephalopathy after initiation of cranial radiation for meningeal leukemia, Lancet, 2 (1978) 834.

    Article  Google Scholar 

  132. Oliff A, Bleyer WA, and Poplack DG. Acute encephalopathy after initiation of cranial radiation for meningeal leukemia, Lancet, 2 (1978) 13.

    Article  PubMed  CAS  Google Scholar 

  133. Jankovic M, Brouwers P, Valsecchi MG, et al. Association of 1800 cGy cranial irradiation with intellectual function in children with acute lymphoblastic leukaemia. International Study Group on Psychosocial Aspects of Childhood Cancer, Lancet, 344 (1994) 224–227.

    Article  PubMed  CAS  Google Scholar 

  134. Moss HA, Nannis ED, and Poplack DG. Effects of prophylactic treatment of the central nervous system on the intellectual functioning of children with acute lymphocytic leukemia, Am. J. Med., 71 (1981) 47–52.

    Article  PubMed  CAS  Google Scholar 

  135. Eiser C. Intellectual abilities among survivors of childhood leukaemia as a function of CNS radiation, Arch. Dis. Child., 53 (1978) 391–395.

    Article  PubMed  CAS  Google Scholar 

  136. Tucker J, Prior PF, Green CR, et al Minimal neuropsychological sequelae following prophylactic treatment of the central nervous system in adult leukemia and lymphoma, Br. J. Cancer, 60 (1989) 775–780.

    Article  PubMed  CAS  Google Scholar 

  137. Sackmann Muriel F, Schere D, Barengols A, et al. Remission maintenance therapy for meningeal leukemia: intrathecal methotrexate and dexamethasone versus intrathecal craniospinal irradiation with a radiocolloid, Br. J. Haematol., 33 (1976) 119–127.

    Google Scholar 

  138. Land VJ, Thomas PRM, Boyett JM, et al. Comparison of maintenance treatment regimens for first central nervous system relapse in children with acute lymphocytic leukemia, Cancer, 56 (1985) 81–87.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Matt E. Kalaycio
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The Cleveland Clinic Taussig Cancer Center, Department of Hematology/Medical Oncology, The Cleveland Clinic Foundation, Cleveland, OH, USA

    Maurie Markman MD (Director, Chairman) (Director, Chairman)

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer Science+Business Media New York

About this chapter

Cite this chapter

Kalaycio, M.E. (2000). Regional Chemotherapy for Treatment and Prophylaxis of Meningeal Leukemia. In: Markman, M. (eds) Regional Chemotherapy. Current Clinical Oncology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-219-7_22

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-219-7_22

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4684-9697-0

  • Online ISBN: 978-1-59259-219-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation